Kathleen Rickard - Concepedia

Author

Kathleen Rickard

Also Known As

Donohue, James, K A Rickard, K RICKARD, K Rickard, K. A. Rickard, K. RICKARD, K. Rickard, K.A. Rickard, KATHLEEN ANN RICKARD, KATHLEEN RICKARD

121

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Research Triangle Park Foundation University of Nebraska Medical Center GlaxoSmithKline (United States)National Jewish Health University of Colorado Denver

About

Kathleen Rickard is an author at Research Triangle Park Foundation specializing in medicine, asthma, and allergy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	35	2.3K
2	Allergy	19	19	1.2K
3	Public Health	4	4	113
4	Education	2	2	78
5	Health Sciences	1	1	23

Kathleen Rickard

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Salmeterol Xinafoate in the Treatment of COPD Donald A. Mahler, James F. Donohue, Robert A. Barbee, CHEST Journal	1999	514
Use of a Long-acting Inhaled β <sub>2</sub> -Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease Stephen I. Rennard, Wayne H. Anderson, Richard ZuWallack, American Journal of Respiratory and Critical Care Medicine	2001	261
Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD Richard ZuWallack, Donald A. Mahler, Donna Reilly, CHEST Journal AsthmaPulmonary CareAdvanced Lung DiseasePulmonary PharmacologyPulmonary Medicine	2001	258
Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast Harold S. Nelson, William W. Busse, Edward Kerwin, Journal of Allergy and Clinical Immunology AsthmaLow-dose Inhaled CorticosteroidPharmacologyPulmonary PharmacologyEffective Asthma Control	2000	226
The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma John J. Condemi, Stanley Goldstein, Christopher Kalberg, Annals of Allergy Asthma & Immunology AsthmaAllergyPharmacologyFluticasone PropionatePharmacotherapy	1999	152
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma William W. Busse, Harold S. Nelson, James Wolfe, Journal of Allergy and Clinical Immunology AsthmaAllergyOral ZafirlukastPulmonary PharmacologyInhaled Salmeterol	1999	144
Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy James E. Fish, Elliot Israel, John Murray, CHEST Journal AsthmaAllergyMedicinePulmonary PharmacologyPulmonary Medicine	2001	141
No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. David B. Allen, Eli O. Meltzer, Robert F. Lemanske, PubMed AsthmaAllergyAllergy MedicineGrowth SuppressionGrowth Rate	2003	131
Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations Jonathan Matz, Amanda Emmett, Kathleen Rickard, Journal of Allergy and Clinical Immunology AsthmaClinical AllergyMedicinePharmacotherapyAllergic Rhinitis	2001	129
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials) Antonio Anzueto, Igor Barjaktarević, Thomas M. Siler, American Journal of Respiratory and Critical Care Medicine	2023	119

Page 1